Daniel Nicholas Ricotta, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hospitalists | 7 | 2023 | 294 | 2.650 |
Why?
|
| Education, Medical | 3 | 2022 | 1725 | 0.960 |
Why?
|
| Internship and Residency | 6 | 2023 | 5865 | 0.920 |
Why?
|
| Legal Guardians | 1 | 2018 | 57 | 0.590 |
Why?
|
| Clinical Competence | 8 | 2022 | 4775 | 0.560 |
Why?
|
| Medicine | 2 | 2023 | 942 | 0.540 |
Why?
|
| Teaching Rounds | 1 | 2020 | 275 | 0.520 |
Why?
|
| Hospital Charges | 1 | 2018 | 357 | 0.520 |
Why?
|
| Burnout, Professional | 3 | 2020 | 701 | 0.500 |
Why?
|
| Referral and Consultation | 4 | 2024 | 3586 | 0.500 |
Why?
|
| Internal Medicine | 2 | 2024 | 1048 | 0.490 |
Why?
|
| Leadership | 2 | 2021 | 1371 | 0.480 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2021 | 1066 | 0.460 |
Why?
|
| Self Efficacy | 1 | 2018 | 632 | 0.450 |
Why?
|
| Patient Care | 1 | 2019 | 622 | 0.440 |
Why?
|
| Physicians | 3 | 2020 | 4580 | 0.440 |
Why?
|
| Inpatients | 3 | 2022 | 2551 | 0.430 |
Why?
|
| Learning | 3 | 2021 | 1739 | 0.420 |
Why?
|
| Intelligence | 1 | 2018 | 921 | 0.420 |
Why?
|
| Apolipoprotein B-100 | 1 | 2012 | 155 | 0.380 |
Why?
|
| Teaching | 4 | 2021 | 1168 | 0.360 |
Why?
|
| Students, Medical | 2 | 2021 | 1927 | 0.360 |
Why?
|
| Oligonucleotides | 1 | 2012 | 582 | 0.320 |
Why?
|
| Curriculum | 5 | 2022 | 3717 | 0.310 |
Why?
|
| Medical Oncology | 1 | 2019 | 2312 | 0.290 |
Why?
|
| Hypercholesterolemia | 1 | 2012 | 1138 | 0.240 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 963 | 0.240 |
Why?
|
| Length of Stay | 1 | 2018 | 6439 | 0.230 |
Why?
|
| Education, Medical, Graduate | 3 | 2022 | 2359 | 0.220 |
Why?
|
| Communication | 3 | 2023 | 3846 | 0.200 |
Why?
|
| Faculty, Medical | 3 | 2021 | 1192 | 0.190 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5331 | 0.190 |
Why?
|
| Humans | 32 | 2024 | 758406 | 0.170 |
Why?
|
| Jurisprudence | 1 | 2019 | 109 | 0.160 |
Why?
|
| Pulmonary Medicine | 2 | 2018 | 221 | 0.160 |
Why?
|
| Blood Sedimentation | 1 | 2019 | 234 | 0.150 |
Why?
|
| Kinesics | 1 | 2017 | 13 | 0.150 |
Why?
|
| Nonverbal Communication | 1 | 2017 | 63 | 0.140 |
Why?
|
| Psychological Theory | 1 | 2018 | 175 | 0.140 |
Why?
|
| Career Choice | 1 | 2023 | 752 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3227 | 0.140 |
Why?
|
| Feedback | 1 | 2020 | 791 | 0.130 |
Why?
|
| Observation | 1 | 2017 | 311 | 0.130 |
Why?
|
| Giant Cell Arteritis | 1 | 2019 | 297 | 0.120 |
Why?
|
| Peer Group | 1 | 2020 | 677 | 0.120 |
Why?
|
| Metformin | 1 | 2022 | 907 | 0.110 |
Why?
|
| Critical Care | 2 | 2018 | 2692 | 0.110 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 643 | 0.110 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 494 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 931 | 0.110 |
Why?
|
| Educational Measurement | 1 | 2018 | 1248 | 0.090 |
Why?
|
| Informed Consent | 1 | 2018 | 1003 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 981 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2018 | 3991 | 0.090 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 526 | 0.090 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 1067 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2012 | 712 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2018 | 1401 | 0.080 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2012 | 459 | 0.080 |
Why?
|
| Motivation | 1 | 2018 | 1996 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2020 | 3891 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2022 | 54137 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 15399 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3242 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2018 | 3433 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 4839 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 20055 | 0.050 |
Why?
|
| Credentialing | 1 | 2019 | 115 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2023 | 1159 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2021 | 42062 | 0.040 |
Why?
|
| Focus Groups | 1 | 2024 | 1384 | 0.040 |
Why?
|
| Hospitalization | 1 | 2018 | 10652 | 0.040 |
Why?
|
| United States | 3 | 2024 | 72136 | 0.030 |
Why?
|
| Patient Simulation | 1 | 2018 | 297 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 7985 | 0.030 |
Why?
|
| Educational Status | 1 | 2023 | 2513 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2018 | 273 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 1529 | 0.030 |
Why?
|
| Manikins | 1 | 2015 | 242 | 0.030 |
Why?
|
| Models, Educational | 1 | 2015 | 373 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2019 | 1084 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2015 | 681 | 0.020 |
Why?
|
| Headache | 1 | 2019 | 1248 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 3069 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 80168 | 0.020 |
Why?
|
| Cross Infection | 1 | 2018 | 1432 | 0.020 |
Why?
|
| Hospitals | 1 | 2022 | 3887 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 3812 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6768 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 219935 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 1115 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12951 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 219568 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15225 | 0.010 |
Why?
|
| Female | 2 | 2019 | 390323 | 0.010 |
Why?
|
| Male | 1 | 2018 | 358747 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 41256 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 168218 | 0.000 |
Why?
|